An evaluation of intracameral mydriasis for routine cataract surgery

Background Intracameral Mydrane might facilitate a more streamlined cataract service and improve the patient experience. There is limited real-world' evidence of its use in a UK setting. Methods As part of a local evaluation of cataract surgery using intracameral Mydrane (group 2; n=60), data were collected on intraoperative pupil size and postoperative visual acuity (VA), as well as the rate of mechanical pupil dilation, intraoperative floppy iris syndrome (IFIS) and complications. Preoperative and theatre turnaround time was recorded and patients completed a validated measure of satisfaction postoperatively. Data were compared with a previous cohort subjected to the existing standard regime of preoperative topical mydriatics (group 1; n=60). Results Postoperative VA was comparable between groups (0.090.16 vs 0.08 +/- 0.15; p=0.59). Pupil size in group 2 was 7.0 +/- 1.0mm prior to capsulorhexis and 6.5 +/- 0.29mm after cortical aspiration, with a smaller pupil in patients on alpha-antagonists (4.7 +/- 1.1mm; p=0.004) at this later time point. Comparing group 2 with group 1, preoperative waiting was less (87 vs 146min; p<0.0001) and satisfaction was higher (76.0 +/- 11.2 vs 66.3 +/- 8.6; p<0.0001), although theatre turnaround time was longer (25 min vs 22 min). Conclusion Intracameral mydriasis was clinically effective in most patients undergoing cataract surgery and might be associated with an improved patient experience and a more streamlined preoperative flow. Mydrane represents a licensed alternative to the off-label use of other intracameral mydriatic agents, but was not judged to be a cost-effective intervention for routine use in this particular setting.